27824334|t|Episomal Nonviral Gene Therapy Vectors Slow Progression of Atherosclerosis in a Model of Familial Hypercholesterolemia
27824334|a|Familial hypercholesterolemia (FH) is a life-threatening genetic disorder characterized by elevated levels of plasma low-density lipoprotein cholesterol (LDL-cholesterol). Current attempts at gene therapy for FH have been limited by the use of strong heterologous promoters which lack genomic DNA elements essential for regulated expression. Here, we have combined a mini-gene vector expressing the human LDLR cDNA from a 10 kb native human LDLR locus genomic DNA promoter element, with an efficient miRNA targeting 3-hydroxy-3-methylgutaryl-coenzyme A reductase (Hmgcr), to further enhance LDLR expression. We show that the combined vector suppresses endogenous Hmgcr transcripts in vivo, leading to an increase in LDLR transgene expression. In a diet-induced Ldlr(-/-) mouse model of FH, we show that administration of the combined vector reduces atherogenic plasma lipids by ~32%. Finally, we demonstrate that our episomal nonviral vectors are able to reduce atherosclerosis by ~40% after 12 weeks in vivo. Taken together, the vector system we describe exploits the normal cellular regulation of the LDLR to provide prolonged expression of LDLR through targeted knockdown of Hmgcr. This novel gene therapy system could act alone, or in synergy with current therapies that modulate intracellular cholesterol, such as statins, greatly enhancing its therapeutic application for FH.
27824334	0	8	Episomal	T114,T123	C0014587
27824334	9	17	Nonviral	T033	C0243095
27824334	18	38	Gene Therapy Vectors	T121	C1517498
27824334	39	55	Slow Progression	T033	C1854494
27824334	59	74	Atherosclerosis	T047	C0004153
27824334	89	118	Familial Hypercholesterolemia	T047	C0020445
27824334	119	148	Familial hypercholesterolemia	T047	C0020445
27824334	150	152	FH	T047	C0020445
27824334	159	175	life-threatening	T033	C2826244
27824334	176	192	genetic disorder	T047	C0019247
27824334	193	206	characterized	T052	C1880022
27824334	210	218	elevated	T080	C3163633
27824334	219	271	levels of plasma low-density lipoprotein cholesterol	T059	C1278149
27824334	273	288	LDL-cholesterol	T109,T123	C0023824
27824334	311	323	gene therapy	T061	C0017296
27824334	328	330	FH	T047	C0020445
27824334	363	369	strong	T080	C0442821
27824334	370	382	heterologous	T080	C0439860
27824334	383	392	promoters	T114,T123	C0035902
27824334	399	403	lack	T080	C0332268
27824334	404	415	genomic DNA	T114	C3272453
27824334	425	434	essential	T080	C0205224
27824334	449	459	expression	T045	C0017262
27824334	475	483	combined	T080	C0205195
27824334	486	502	mini-gene vector	T114	C0017397
27824334	503	513	expressing	T045	C0017262
27824334	518	523	human	T016	C0086418
27824334	524	528	LDLR	T028	C1366529
27824334	529	533	cDNA	T114	C0006556
27824334	554	559	human	T016	C0086418
27824334	560	564	LDLR	T028	C1366529
27824334	565	570	locus	T028	C0678933
27824334	571	582	genomic DNA	T114	C3272453
27824334	583	591	promoter	T114,T123	C0035902
27824334	609	618	efficient	T080	C0442799
27824334	619	624	miRNA	T114,T123	C1101610
27824334	635	681	3-hydroxy-3-methylgutaryl-coenzyme A reductase	T028	C1415615
27824334	683	688	Hmgcr	T028	C1415615
27824334	702	709	enhance	T052	C2349975
27824334	710	714	LDLR	T028	C1366529
27824334	715	725	expression	T045	C0017262
27824334	744	752	combined	T080	C0205195
27824334	753	759	vector	T114	C0017397
27824334	760	770	suppresses	T045	C0038855
27824334	771	781	endogenous	T169	C0205227
27824334	782	787	Hmgcr	T028	C1415615
27824334	788	799	transcripts	T114	C1519595
27824334	800	807	in vivo	T082	C1515655
27824334	823	831	increase	T169	C0442805
27824334	835	839	LDLR	T028	C1366529
27824334	840	849	transgene	T028	C0282641
27824334	850	860	expression	T045	C0017262
27824334	880	889	Ldlr(-/-)	T028	C1366529
27824334	890	901	mouse model	T015	C0206745
27824334	905	907	FH	T047	C0020445
27824334	922	936	administration	T061	C1533734
27824334	944	952	combined	T080	C0205195
27824334	953	959	vector	T114	C0017397
27824334	960	967	reduces	T080	C0392756
27824334	968	993	atherogenic plasma lipids	T059	C1278073
27824334	1036	1061	episomal nonviral vectors	T114	C0017397
27824334	1074	1080	reduce	T080	C0392756
27824334	1081	1096	atherosclerosis	T047	C0004153
27824334	1114	1119	weeks	T079	C0439230
27824334	1120	1127	in vivo	T082	C1515655
27824334	1149	1155	vector	T114	C0017397
27824334	1156	1162	system	T169	C0449913
27824334	1188	1194	normal	T080	C0205307
27824334	1195	1214	cellular regulation	T043	C0596286
27824334	1222	1226	LDLR	T028	C1366529
27824334	1238	1247	prolonged	T079	C0439590
27824334	1248	1258	expression	T045	C0017262
27824334	1262	1266	LDLR	T028	C1366529
27824334	1284	1293	knockdown	T063	C2350567
27824334	1297	1302	Hmgcr	T028	C1415615
27824334	1315	1327	gene therapy	T061	C0017296
27824334	1328	1334	system	T169	C0449913
27824334	1358	1365	synergy	T080	C0205195
27824334	1394	1402	modulate	T082	C0443264
27824334	1403	1416	intracellular	T082	C0178719
27824334	1417	1428	cholesterol	T109,T123	C0008377
27824334	1438	1445	statins	T109,T121	C0360714
27824334	1469	1492	therapeutic application	T061	C0087111
27824334	1497	1499	FH	T047	C0020445